MSD SVP Deepak Khanna: Taking a Europe-Wide Approach in the Fight Against Cancer
There are over 3.5 million diagnoses and 1.3 million deaths from cancer in the EU each year and cancer is set to become the region’s leading cause of death without…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Belgium s.a. – n.v.
Park Lane G, Culliganlaan 2G
1831 Diegem
Belgium
Phone: +32 2 219 12 18
Fax: +32 2 219 23 56
There are over 3.5 million diagnoses and 1.3 million deaths from cancer in the EU each year and cancer is set to become the region’s leading cause of death without…
Joris Van Assche, managing director of the Belgian association for accessible medicines, Medaxes, highlights the need for a stronger policy to create a more positive environment for generic and biosimilar…
Speaking at the 2020 European Cancer Forum in Brussels, MSD’s Deepak Khanna outlines the progress that the company is making at the forefront of oncological innovation, the importance of multi-stakeholder…
After reaching revenues of EUR 2.323 billion in the first six months of 2019, UCB announced on December 18 that it will build an innovative multi-product biological manufacturing facility on…
The second edition of the European Cancer Forum was held in Brussels, Belgium on Tuesday, 29 January 2020. Hosted by MSD in collaboration with the European Cancer Patient Coalition (ECPC),…
Jean-Christophe Tellier became UCB’s CEO on January 1, 2015 only a few years joining the company in 2011. Before taking on the role Tellier held positions as executive VP of…
Annie Hubert, Senior Director, EU Section & Public Policy for the Alliance for Regenerative Medicine (ARM) describes some of the issues that companies in the advanced therapies field are facing…
One of NNE Pharmaplan’s latest exciting news is that last year you established offices to accommodate your existing customers in Belgium. What were the strategic motivations for establishing a presence…
Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout…
Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout…
Mrs van der Kamp, you launched your career as a strategy consultant however, since then you have moved into the pharmaceutical industry by joining Novartis where you quickly worked your…
With an expenditure of more than 10% of GDP on health, Belgium maintains one of the world’s leading healthcare systems. That said, could you please comment on the current state…
See our Cookie Privacy Policy Here
